Iterum Therapeutics (ITRM) EBT (2017 - 2022)
Historic EBT for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to -$5.0 million.
- Iterum Therapeutics' EBT fell 2438.29% to -$5.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$44.1 million, marking a year-over-year increase of 5142.69%. This contributed to the annual value of -$24.9 million for FY2024, which is 3695.35% up from last year.
- Per Iterum Therapeutics' latest filing, its EBT stood at -$5.0 million for Q4 2022, which was down 2438.29% from -$29.7 million recorded in Q3 2022.
- In the past 5 years, Iterum Therapeutics' EBT registered a high of $7.9 million during Q2 2021, and its lowest value of -$98.9 million during Q1 2021.
- Moreover, its 5-year median value for EBT was -$14.0 million (2018), whereas its average is -$18.3 million.
- As far as peak fluctuations go, Iterum Therapeutics' EBT surged by 16416.59% in 2021, and later tumbled by 82511.61% in 2022.
- Over the past 5 years, Iterum Therapeutics' EBT (Quarter) stood at -$24.1 million in 2018, then decreased by 0.1% to -$24.1 million in 2019, then skyrocketed by 50.75% to -$11.9 million in 2020, then surged by 66.17% to -$4.0 million in 2021, then dropped by 24.38% to -$5.0 million in 2022.
- Its last three reported values are -$5.0 million in Q4 2022, -$29.7 million for Q3 2022, and -$6.4 million during Q2 2022.